Company Report
Last edited one year ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#3
Performance (91m)
17.9% pa
Followed by
1398
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Defensive or Growth?
stale
Last edited one year ago

Perhaps both. Today, Wednesday 4th September 2024, the ASX got smashed and every sector was in the red, following falls in the US on their Tuesday (Monday was a public holiday over there for Labor Day).

But not ResMed, or FPH either; both made new 12-month highs today:

c24794d45fb0ce7c2f5af5ed1892978a493926.png

Tables sourced from: https://marcustoday.com.au/

3d59345eff5413274dce3c65691490520ee47a.png

Below, not many on the left side (12 month highs) but they ran out of room for the 12 month lows (on the right):

1e8567417145f95263bc73ff7e7a31daa135eb.png

After Industrials, Healthcare was the second least worst sector today, and we have those two CPAP providers heading up the new 12-month high share price list. As well as IXI - the iShares Global Consumer Staples ETF that tracks the performance of the S&P Global 1200 Consumer Staples (Sector) Capped Index, so the sort of thing that people turn to when the world goes pear-shaped - even in a zombie apocalypse, they'll still be selling tins of baked beans I suppose.

Health care and consumer staples are generally considered "defensive" sectors" - so "risk off" sectors, when people just aren't feeling the optimism around the near-term potential of share-markets.

Only thing is - when you look at the charts of ResMed and Fisher & Paykel Healthcare, they do NOT look like defensive stocks, they looks very much like growth stocks - their one year charts are all bottom left to top right.

One year ago, I was arguing that while Ozempic and the like did NOT present a major threat to the future viability and growth of ResMed, I wouldn't invest in them because I felt that people would always be searching for better options for their OSA treatment, due to the invasive nature of CPAP and the drawbacks of being connected to a machine via a tube while you sleep. In short, I felt that CPAP as an industry was ripe for disruption by any tech that was easier to use.

So I thought that future competition from something other than CPAP - for OSA specifically - was the thing that concerned me, so I was never going to be a RMD or FPH investor.

Well, here we are, less than a year later and I'm using a Phillips DreamStation CPAP machine connected to a ResMed mask every night after being diagnosed with severe OSA (just shy of 60 episodes per hour, so around 1 per minute on average) and it's fair to say, tending towards the possibility of having a little rethink about my earlier assumptions and opinions...